Fig. 10.

Trimannose decorated lipopolyplex targets splenic DCs for enhanced delivery and translation of modified mRNA, hence increases anti-tumor immunity. (a) Schematic illustration of the preparation of LPR nanoparticles. (b) Bioluminescence imaging revealed that FFL-LPR-mRNA targeted the spleens of mice at 24 h after systemic administration. (c) E7-specific CD8⁺ T cells of mice immunised with different nanoformulations as indicated. (d) An experimental timeline of a therapeutic TC-1 tumor model and average TC-1 tumor growth curves of mice vaccinated with different nanoformulations as indicated. Reprinted with permission from Ref. [132]. Copyright 2018, American Chemical Society.